Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 7;102(27):e34228.
doi: 10.1097/MD.0000000000034228.

Bibliometric and visualized analysis of the top-100 highly cited articles on immunotherapy for endometrial cancer

Wanzhen Zheng  1   2 , Yinjie Wu  1 , Yu Wang  2 , Jiaxin Cheng  2 , Wenjing Shen  1
Affiliations

Bibliometric and visualized analysis of the top-100 highly cited articles on immunotherapy for endometrial cancer

Wanzhen Zheng et al. Medicine (Baltimore). .

Abstract

Background: Immunotherapy is a promising method for the treatment of endometrial cancer (EC). We aimed to conduct a comprehensive bibliometric study of the top 100 most-cited publications on immunotherapy for EC and provide a reference for future research.

Methods: Global publications on immunotherapy for EC published from 1985 to the present in the Web of Science core database were retrieved. We focused on the study of the top 100 most-cited articles by extracting information such as year, country, journal, author, institution, literature, and keywords. Microsoft Excel, VOSviewer, and R were used to perform descriptive statistics and visual analyses.

Results: The top 100 most-cited articles were published between 2002 and 2022, including 70 original papers and 30 reviews. The total frequency of citations per article ranges from 15 to 287. Developed countries dominated these publications, with the United States contributing the most (50 articles). According to Bradford Law, 6 journals, including Gynecologic Oncology and the Journal of Clinical Oncology, are highly recommended. Santin A. D. from Yale University and Makker.V. from Memorial Sloan Kettering Cancer Center have made positive contributions. Among the top ten most-cited articles, 7 focused on clinical trials exploring the efficacy of immunotherapy drugs, of which 4 were lenvatinib combined with pembrolizumab for the treatment of advanced EC. The immune-microenvironment, immune antitumor mechanisms, immunomodulatory drugs, especially anti-pd-1/pd-l1 checkpoint inhibitors, and their clinical trials are the focus of current research.

Conclusion: The attention of researchers from different countries to EC immunotherapy, especially immunosuppressants, has brought a breakthrough in this field. A large number of clinical trials have evaluated the efficacy and safety of immune agents, and immune combination therapy (especially targeted therapy) shows positive therapeutic promise. Immunodrug sensitivity and adverse events remain urgent issues. The key to promoting the development of EC immunotherapy is to select the best patients according to the molecular classification and immunophenotype such as tumor mutation load, MMR status, pd-l1 expression, tumor infiltrating immune cells to truly achieve accurate and personalized treatment. More new and influential EC immunotherapies, such as adoptive cell immunotherapy, still need to be explored in future clinical practice.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Trend chart of the annual number of published articles of the top 100 most-cited articles.
Figure 2.
Figure 2.
The contributions of different countries to the top 100 most-cited articles.
Figure 3.
Figure 3.
The cooperation networks between different countries which contributed the top 100 highly cited articles.
Figure 4.
Figure 4.
Visualization of national cooperative networks on a world map. The lines represent cooperation between countries, and the width of the lines represents the number of coauthored articles.
Figure 5.
Figure 5.
The cooperative network between organizations which contributed at least 2 of the top 100 highly cited articles.
Figure 6.
Figure 6.
the annual publication information of 13 authors who contributed at least 5 of the top 100 most-cited articles.
Figure 7.
Figure 7.
The cooperative between authors who contributed at least 2 of the top 100 highly cited articles.
Figure 8.
Figure 8.
Core journals in which the top100 most-cited articles were published.
Figure 9.
Figure 9.
Keyword networks with collinear frequency greater than or equal to 3.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Zhang S, Gong T-T, Liu F-H, et al. . Global, regional, and national burden of endometrial cancer, 1990-2017: results from the global burden of disease study, 2017. Front Oncol. 2019;9:1440. - PMC - PubMed
    1. Sung H, Ferlay J, Siegel RL, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. - PubMed
    1. Morice P, Leary A, Creutzberg C, et al. . Endometrial cancer. Lancet. 2016;387:1094–108. - PubMed
    1. Brooks RA, Fleming GF, Lastra RR, et al. . Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019;69:258–79. - PubMed
    1. Miller D, Filiaci V, Fleming G, et al. . Randomized phase Ill noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2012;125:771.